Contineum Therapeutics, Inc.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Contineum Therapeutics, Inc. (NASDAQ:CTNM) has received the result biotech investors never want to see: one of its partnered drugs missed the primary endpoint of a Phase 2 trial. JNJ-5120/PIPE-307, which Contineum developed and Johnson & Johnson (NYSE:JNJ) is advancing under a global license and development agreement, failed to demonstrate the required efficacy in the Phase […]
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
SAN DIEGO, July 30, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones.
Congressional Trades in $CTNM
No disclosed congressional trades found in $CTNM.
Insider Trades (Form 4)
Stengone Carmine N.
Stengone Carmine N.
Stengone Carmine N.
Lorrain Daniel S.
Miralles Gines Diego
Lyons-Williams Lori
Ware Olivia C
Schimmelpennink Evert B.
Key People
Stengone Carmine N
CEO and President
Lorrain Daniel S
Chief Scientific Officer
Lyons-Williams Lori
Director
Brady Todd R
Director
Miralles Gines Diego
Director
Schimmelpennink Evert B
Director
Ignelzi Troy A
Director
Ware Olivia C
Director
Boyce Sarah
Director
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro